flora peyvandi/X
Dec 8, 2025, 07:42
Flora Peyvandi: Anti-emicizumab Antibodies and Their Relevance in Clinical Practice
Flora Peyvandi, Professor of Internal Medicine at the University of Milan and former President of ISTH, shared a post on X:
“The development of anti-emicizumab antibodies is a rare event, particularly those with neutralizing activity. Routine monitoring should be reserved only for patients with clinical manifestations of bleeding when therapy failure is suspected.”
Title: Anti-emicizumab antibodies and their relevance in clinical practice
Authors: Carla Valsecchi, Lucia Schiavone, Sara Arcudi, Adriana Torri, Cristina Novembrino, Flora Peyvandi
Read the full article.
More posts featuring Flora Peyvandi on Hemostasis Today.
-
Jul 18, 2026, 15:49Heghine Khachatryan: ISTH 2026 – Final Day Highlights
-
Jul 18, 2026, 15:40Marc Carrier: New ISTH 2026 Data May Simplify DVT Evaluation During Pregnancy
-
Jul 18, 2026, 15:38Hermine Sayiyan: Dreams Do Come True – Often When We Least Expect Them
-
Jul 18, 2026, 15:31Alyaa Al-Mughairy: Presenting Real-World Emicizumab Data at the ISTH 2026 Middle East Summit
-
Jul 18, 2026, 15:25Rim Diab: Presenting Protein S Research as a Rebalancing Strategy at ISTH 2026
-
Jul 18, 2026, 15:22Owen McCarty: Honored to Speak at the 1st Mediterranean Platelet Symposium
-
Jul 18, 2026, 15:18Strengthening Regional Learning for Hemophilia and Sickle Cell Disease Care – Novo Nordisk
-
Jul 18, 2026, 14:54Fabien Mselati: Reflecting on 25 Years of Hemophilia Progress
-
Jul 18, 2026, 14:50Nikola Pantic: Grateful for the People Who Made ISTH 2026 Special